Show simple item record

dc.contributor.authorSeo, Young-Eun
dc.contributor.authorSuh, Hee-Won
dc.contributor.authorBahal, Raman
dc.contributor.authorJosowitz, Alexander
dc.contributor.authorZhang, Junwei
dc.contributor.authorSong, Eric
dc.contributor.authorCui, Jiajia
dc.contributor.authorNoorbakhsh, Seth
dc.contributor.authorJackson, Christopher
dc.contributor.authorBu, Tom
dc.contributor.authorPiotrowski-Daspit, Alexandra
dc.contributor.authorBindra, Ranjit
dc.contributor.authorSaltzman, W Mark
dc.date.accessioned2019-06-09T01:37:09Z
dc.date.available2019-06-09T01:37:09Z
dc.date.issued2019
dc.identifier.issn0142-9612
dc.identifier.doi10.1016/j.biomaterials.2019.02.016
dc.identifier.urihttp://hdl.handle.net/10072/383812
dc.description.abstractGlioblastoma (GBM) is the most common and deadly form of malignant brain tumor in the United States, and current therapies fail to provide significant improvement in survival. Local delivery of nanoparticles is a promising therapeutic strategy that bypasses the blood-brain barrier, minimizes systemic toxicity, and enhances intracranial drug distribution and retention. Here, we developed nanoparticles loaded with agents that inhibit miR-21, an oncogenic microRNA (miRNA) that is strongly overexpressed in GBM compared to normal brain tissue. We synthesized, engineered, and characterized two different delivery systems. One was designed around an anti-miR-21 composed of RNA and employed a cationic poly(amine-co-ester) (PACE). The other was designed around an anti-miR-21 composed of peptide nucleic acid (PNA) and employed a block copolymer of poly(lactic acid) and hyperbranched polyglycerol (PLA-HPG). We show that both nanoparticle products facilitate efficient intracellular delivery and miR-21 suppression that leads to PTEN upregulation and apoptosis of human GBM cells. Further, when administered by convection-enhanced delivery (CED) to animals with intracranial gliomas, they both induced significant miR-21 knockdown and provided chemosensitization, resulting in improved survival when combined with chemotherapy. The challenges involved in optimizing the two delivery systems differed, and despite offering distinct advantages and limitations, results showed significant therapeutic efficacy with both methods of treatment. This study demonstrates the feasibility and promise of local administration of miR-21 inhibiting nanoparticles as an adjuvant therapy for GBM.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier Science
dc.relation.ispartofpagefrom87
dc.relation.ispartofpageto98
dc.relation.ispartofjournalBIOMATERIALS
dc.relation.ispartofvolume201
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchcode3211
dc.titleNanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorBindra, Randy


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record